{
  "id": 12717848,
  "title": "FDA Expands Indication for Urticaria Drug to Treat Symptomatic Dermographism",
  "url": "https://urgent.news/2026/10/07/fda-expands-indication-for-urticaria-drug-to-treat-symptomatic",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-07T20:14:19.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/dermatology/generaldermatology/123309"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- The FDA expanded the indication of the Bruton's tyrosine kinase (BTK) inhibitor remibrutinib (Rhapsido) to treat symptomatic dermographism, the most common form of chronic inducible urticaria, Novartis announced Thursday. The...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}